Condition
Psoriatic Erythroderma
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 3 (2)
P 4 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01680159Phase 3Completed
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
NCT02052609Phase 3Completed
A Phase 3 Clinical Study of KHK 4827
NCT05144165Unknown
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
NCT04183881Phase 4Completed
A Phase 4 Clinical Study of Brodalumab
Showing all 4 trials